Shellie Faris, MD

Articles

A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer

Mehmet Sitki Copur, MD, FACP;Jacqueline R. Kelly, MD, MSc;Nicholas Lintel, MD;Bronson Riley, MS;Daniel J. Herold, MD;Shellie Faris, MD;Whitney Wedel, MD;Adam J. Horn, MD

August 13th 2021

This study presents a male breast cancer case with a germline BRCA2 mutation and discusses the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of the disease.

Recurrent EGFR-Mutated Non–Small Cell Lung Cancer Discovered by Abnormal Mammogram: Adjuvant/Frontline Metastatic Management Options

Mehmet Sitki Copur, MD;Rudy P. Lackner, MD;Adam J. Horn, MD;Thomas Zusag, MD;Shellie Faris, MD;Paul Rodriguez, MD

September 21st 2020

ABSTRACT: Breast metastasis from extramammary malignancy is rare, with a reported incidence rate of 0.4% to 1.3% in the published literature. The primary malignancies that most commonly metastasize to the breast are leukemia, lymphoma, and malignant melanoma. Here, we report a very rare case of metastatic EGFR-mutated non–small cell lung cancer (NSCLC) in the breast detected by screening mammography. The patient had initially been diagnosed with a clinical stage IIIA NSCLC and had been treated with neoadjuvant chemoradiation followed by curative-intent surgery. Several interesting aspects of the case, along with a discussion of evolving adjuvant and frontline metastatic management options in EGFR-mutated NSCLC, will be presented.